The syndrome of Parkinsonism is characterised by rigidity, tremor and bradykinesia. It has many causes. The most common (85%) is Parkinson's disease (PD), an idiopathic neurological disease involving the extrapyramidal system. It is more common in the elderly (prevalence 1% in patients >65 yr), but it can also afflict the young. It is likely that the anaesthetist will encounter patients with PD more frequently because of the growing elderly surgical population. Optimal anaesthetic management requires an understanding of the condition, its treatment, drug interactions and anaesthetic hazards and a plan to ensure administration of anti-Parkinsonian medication in the peri-operative period in order to avoid complications of poor control.
Causes of Parkinsonism
In idiopathic PD, dopaminergic neurones in the substantia nigra are lost and intracellular inclusion bodies called Lewy bodies are seen in remaining neurones. It is thought that > 80% of neurones are lost before the syndrome becomes apparent clinically. There are many causes of Parkinsonism (Table 1 ) but the common underlying pathology is loss of dopaminergic transmission in the substantia nigra.
Clinical features
The cardinal bedside features of PD include akinesia, rigidity, tremor and postural imbalance. However, PD is more than a disorder of voluntary motor control; it involves the autonomic, cognitive, emotional, sensory and visual systems. Many of the multisystemic features are pertinent to the anaesthetist (Table 2 ). Disease pattern varies between patients and with time, but it tends to be progressive. Severe disease often demands more complex and less successful treatment regimens.
Pharmacological management
The indications, mechanism of action, sideeffects and interactions of commonly-used drugs are shown in Table 3 . A large number of drugs are available and treatment depends upon the stage and features of the disease, side-effect tolerance and ease of compliance. When PD is a nuisance rather than a disability, it is not obligatory to start treatment. Patients with relatively mild PD may be managed on a dopamine agonist, monoamine oxidase-B inhibitor or amantadine alone. Dopamine does not readily pass the bloodbrain barrier. The most effective and commonly encountered treatment is levodopa. This is a dopamine precursor which undergoes conversion, peripherally and within the CNS, to dopamine by the enzyme dopa decarboxylase ( Fig. 1) . Levodopa is co-administered with a peripherally acting dopa decarboxylase inhibitor (DDI), e.g. benserazide. This allows a reduction in the dose of levodopa and reduces peripheral dopaminergic side-effects (tachycardia, dysrrhythmias, nausea and vomiting). Most patients on a levodopa-DDI regimen will experience end-of-dose 'off' periods where the symptoms return only a few hours after the last dose. Some patients will experience peak dose dyskinesias (choreiform writhing movements) corresponding to peak plasma concentrations of dopamine; these dyskinesias are just as disabling as 'off' periods. Increasing the dose of levodopa to treat 'off' periods may worsen dyskinesias. These problems with levodopa tend to reduce its usefulness over time.
Several strategies have been devised to minimise 'off' periods and dyskinesias. Severe 'off' periods and dyskinesias may respond to subcutaneous intermittent bolus injections or infusions of apomorphine (dopamine agonist) -an effective, but underused, treatment in PD. Apomorphine is of relevance to anaesthetists as it provides a means of treating PD in the peri-operative period which does not rely on the enteral route.
A sudden dramatic worsening of symptoms may be seen on the sudden discontinuation of virtually all classes of antiParkinsonian drugs. Therefore, this should be avoided in the perioperative period. Abrupt discontinuation of PD therapy (i.e. abrupt cessation of central dopaminergic transmission) can also precipitate the neuroleptic malignant syndrome. This is encountered more frequently in psychiatric patients, where it is precipitated by the administration of neuroleptic drugs. Neuroleptic malignant syndrome is characterised by rigidity, akinesia, hyperthermia, autonomic dysfunction, sweating and muscle breakdown (elevated plasma concentrations of creatine kinase). If this syndrome is suspected in a PD patient, anti-Parkinsonian agents should be restarted as a matter of urgency (mortality rate 10%). Further management is essentially supportive.
Peri-operative management
There is no evidence-based ideal method of anaesthesia. The following are suggestions and observations to aid successful management.
Organisational factors
The anaesthetist should get good warning of a planned admission so that the patient can be assessed pre-operatively. The patient's regular PD physician should be informed and involved in peri-operative management. Some hospitals have a PD nurse. Ideally, management should be optimised before surgery and patients placed first on the list so that the timing of surgery and drug administration is predictable and the risks of cancellation minimised. If surgery is postponed, antiParkinsonian treatment should be started without delay.
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Anaesthetic factors
Pre-operative assessment should consider the various complications of PD and may be hindered by sub-optimal symptom control. In fact, a patient with severe unalleviated PD may mistakenly be labelled as demented. The patient should be warned that they might not enjoy their normal level of control in the peri-operative period. As a general rule, it is desirable to stop PD treatment as late as possible pre-operatively and to restart it as soon as possible postoperatively. This may be impossible in patients who are unable to swallow or have had major abdominal surgery. Levodopa can be administered via a nasogastric or nasojejunal tube (levodopa is rapidly absorbed in the proximal small bowel).
Apomorphine is a useful treatment in the peri-operative period although the published evidence for the approaches suggested below is scant. Patients already established on apomorphine infusions should continue with this treatment throughout the operative period. Patients undergoing planned elective surgery who are unlikely to be able to take their medication for some time after surgery should undergo an apomorphine challenge to establish the bolus dose of apomorphine required to abolish their Parkinsonism and to check that no severe adverse effects of apomorphine occur (e.g. profound hypotension). Patients should be pretreated with domperidone 20 mg tds for 3 days prior to the challenge. A subcutaneous infusion of apomorphine is then commenced for 1-2 days prior to surgery. The exact dose depends on the challenge dose of apomorphine required and the clinical response, but is often 30-40 mg over 16 h. Domperidone 30 mg tds can be administered by rectal suppository.
Emergency major surgery in PD is more difficult to manage, though often a test dose of apomorphine can still be given to check for major adverse events before an infusion is started. However, it should be remembered that apomorphine can cause significant hypotension making pre-operative and operative use potentially hazardous. Apomorphine infusions can be continued in the postoperative period until oral medication can be restarted.
Airway assessment is important as patients may display a flexion deformity of the neck making intubation difficult. Sialorrhoea (drooling) or pooling of saliva can indicate the need for a pre-operative drying agent. Centrally-acting anticholinergic agents may precipitate the central anticholinergic syndrome (confusion, somnolence and restlessness). Glycopyrrolate has peripheral effects only and has been used in PD patients. PD is more common in elderly patients where co-existing disease is more common. Pre-operative investigations should be appropriate to the individual patient's age, condition and proposed surgery. Anaesthetic monitoring should be standard but extended where necessary. Artefacts may hinder monitoring (e.g. resting tremor can simulate ventricular tachycardia on ECG and render non-invasive blood pressure devices unreliable).
The major anaesthetic decision is between a regional and general technique, or both. The prime advantage of a regional technique is that the patient remains conscious and can commence normal medication soon after the procedure, providing the gastrointestinal tract is still functional. Spinal or epidural anaesthesia may preserve gastrointestinal peristalsis better than a general anaesthetic involving opioids.
However, regional techniques may be technically difficult because of tremor and rigidity. Twitches from peripheral nerve stimulators may be hard to discern. A regional technique will not abolish tremor in regions without motor blockade and this may hinder surgery and anaesthetic monitoring. In one case report, anti-Parkinsonian medication wore off during surgery under a regional anaesthesia necessitating further oral treatment. Entacapone (Table 3 ) may complicate the use of vasoconstrictors and/or inotropes if the blood pressure falls as a consequence of sympathetic blockade. A demented patient with PD may not be able to co-operate.
General anaesthesia offers the advantages of a still patient. A nasogastric or nasojejunal tube can be inserted to facilitate administration of medications postoperatively. Several drugs used during general anaesthesia may worsen PD, for example propofol, halothane, neuroleptics and opioids. Selegiline and meperidine interact to cause delirium, confusion, agitation and muscular rigidity. Succinylcholine has precipitated hyperkalaemia. Propofol is unusual in that it may have dopaminelike effects in some patients; for example, improvement of Parkinson's disease tremor and development of dyskinesias have been reported. General anaesthesia may worsen an already compromised cough and respiratory function. Nausea and vomiting may hinder administration of enteral medication.
Recovery and rehabilitation
Opioids are often necessary after major surgery but should be used with care. Patients with PD may not be able to operate a patient-controlled analgesia device or communicate needs for analgesia effectively. Animal studies and a small number of case reports suggest that opioid analgesics can worsen rigidity. It is likely that this occurs at doses far in excess of those required for analgesia but idiosyncratic reactions have been reported in normal patients to conventional doses of opioids (e.g. fentanyl 150 µg). Non-steroidal anti-inflammatory drugs can be used, but the normal precautions in elderly patients apply. Paracetamol has no adverse effect. The effects of opioids in neuraxial local anaesthetic solutions are unknown.
Postoperative nausea and vomiting should not be treated with centrally acting antidopaminergic drugs (e.g. prochlorperazine). Alternatives include cyclizine and ondansetron. However, vigilance is required as extrapyramidal and movement disorders can occur with all these drugs. A balanced anti-emesis regimen including antidopaminergic drugs is not appropriate for these patients.
Care should be taken to keep the patient adequately hydrated in the peri-operative period as hypovolaemia/dehydration may worsen orthostatic hypotension and impair rehabilitation. Good control of PD, respiratory and musculoskeletal physiotherapy and satisfactory analgesia will help to avoid the postoperative complications of thrombo-embolism, pressure area damage, sputum retention and aspiration.
Postoperative delirium occur frequently (co-existing dementia and systemic disease, medication, centrally acting anaesthetic drugs and cerebrovascular problems). Neuroleptic agents should not be used to treat confusion in patients with features of Parkinsonism.
